Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110.
Several studies have shown that when purified from a tumor, certain heat shock proteins (HSPs) can function as effective vaccines against the same tumor by virtue of their ability to bind tumor-specific peptides. However, only a small fraction of the associated peptides would be expected to be immunogenic, in addition to which, the clinical application of this vaccine requires the availability of a surgical specimen of sufficient quantity for purification of the HSP. The present study describes a new approach for the development of natural HSP vaccines that do not have these limitations. This approach uses a recombinant HSP that is noncovalently bound to a recombinant tumor protein antigen by heat shock. HSP110 has been selected for this purpose, because it has been shown to be a highly efficient molecular chaperone in binding to large protein substrates. We show that a "natural chaperone complex" between HSP110 and the intracellular domain (ICD) of human epidermal growth factor receptor 2 protein (HER-2)/neu is formed by heat shock. This HSP110-ICD vaccine elicited both CD8(+) and CD4(+) T-cell responses against ICD as determined by an antigen-specific IFN-gamma production in an enzyme-linked immunospot assay (ELISPOT). In vivo depletion studies revealed that the CD8(+) T-cell response was independent of CD4(+) T-cell help. The HSP110-ICD complex also significantly enhanced ICD-specific antibody responses relative to that seen with ICD alone. No CD8(+) T cell or antibody response was detected against HSP110. The use of recombinant HSP110 to form natural chaperone complexes with large protein antigens represents a new and powerful approach for the design of protein-targeted cancer vaccines.
Manjili
Masoud H
MH
Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo New York 14263, USA.
Henderson
Robert
R
Wang
Xiang-Yang
XY
Chen
Xing
X
Li
Ying
Y
Repasky
Elizabeth
E
Kazim
Latif
L
Subjeck
John R
JR
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D005260:Female; D050957:HSP110 Heat-Shock Proteins; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology* / Q000378:metabolism; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology* / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology
D019496:Cancer Vaccines; D000939:Epitopes; D050957:HSP110 Heat-Shock Proteins; D018840:HSP70 Heat-Shock Proteins; D007074:Immunoglobulin G; D007371:Interferon-gamma; D018719:Erb-b2 Receptor Tyrosine Kinases; D014614:Vaccines, Synthetic; C490783:Hsp105 protein, mouse